nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosutinib—Abdominal tenderness—Octreotide—thymus cancer	0.0226	0.128	CcSEcCtD
Bosutinib—Pancreatitis acute—Octreotide—thymus cancer	0.0124	0.0703	CcSEcCtD
Bosutinib—Blood creatine phosphokinase increased—Octreotide—thymus cancer	0.0083	0.0472	CcSEcCtD
Bosutinib—Acne—Octreotide—thymus cancer	0.00679	0.0386	CcSEcCtD
Bosutinib—Hyperkalaemia—Octreotide—thymus cancer	0.00561	0.0319	CcSEcCtD
Bosutinib—Gastrointestinal haemorrhage—Octreotide—thymus cancer	0.00414	0.0236	CcSEcCtD
Bosutinib—Dehydration—Octreotide—thymus cancer	0.00385	0.0219	CcSEcCtD
Bosutinib—Abdominal pain upper—Octreotide—thymus cancer	0.00379	0.0215	CcSEcCtD
Bosutinib—Nasopharyngitis—Octreotide—thymus cancer	0.00371	0.0211	CcSEcCtD
Bosutinib—Gastritis—Octreotide—thymus cancer	0.00367	0.0208	CcSEcCtD
Bosutinib—Influenza—Octreotide—thymus cancer	0.00358	0.0204	CcSEcCtD
Bosutinib—Bronchitis—Octreotide—thymus cancer	0.00344	0.0196	CcSEcCtD
Bosutinib—Abdominal discomfort—Octreotide—thymus cancer	0.00343	0.0195	CcSEcCtD
Bosutinib—Upper respiratory tract infection—Octreotide—thymus cancer	0.00333	0.0189	CcSEcCtD
Bosutinib—Pneumonia—Octreotide—thymus cancer	0.00321	0.0183	CcSEcCtD
Bosutinib—Hepatobiliary disease—Octreotide—thymus cancer	0.00302	0.0172	CcSEcCtD
Bosutinib—Hepatitis—Octreotide—thymus cancer	0.00287	0.0163	CcSEcCtD
Bosutinib—Oedema peripheral—Octreotide—thymus cancer	0.00282	0.0161	CcSEcCtD
Bosutinib—Tinnitus—Octreotide—thymus cancer	0.00267	0.0152	CcSEcCtD
Bosutinib—Cardiac disorder—Octreotide—thymus cancer	0.00266	0.0151	CcSEcCtD
Bosutinib—Immune system disorder—Octreotide—thymus cancer	0.00259	0.0147	CcSEcCtD
Bosutinib—Malnutrition—Octreotide—thymus cancer	0.0025	0.0142	CcSEcCtD
Bosutinib—Back pain—Octreotide—thymus cancer	0.00241	0.0137	CcSEcCtD
Bosutinib—Ill-defined disorder—Octreotide—thymus cancer	0.00232	0.0132	CcSEcCtD
Bosutinib—Anaemia—Octreotide—thymus cancer	0.00231	0.0131	CcSEcCtD
Bosutinib—Malaise—Octreotide—thymus cancer	0.00225	0.0128	CcSEcCtD
Bosutinib—Cough—Octreotide—thymus cancer	0.00218	0.0124	CcSEcCtD
Bosutinib—Arthralgia—Octreotide—thymus cancer	0.00212	0.0121	CcSEcCtD
Bosutinib—Chest pain—Octreotide—thymus cancer	0.00212	0.0121	CcSEcCtD
Bosutinib—Myalgia—Octreotide—thymus cancer	0.00212	0.0121	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Octreotide—thymus cancer	0.00211	0.012	CcSEcCtD
Bosutinib—Discomfort—Octreotide—thymus cancer	0.0021	0.0119	CcSEcCtD
Bosutinib—Oedema—Octreotide—thymus cancer	0.00204	0.0116	CcSEcCtD
Bosutinib—Anaphylactic shock—Octreotide—thymus cancer	0.00204	0.0116	CcSEcCtD
Bosutinib—Infection—Octreotide—thymus cancer	0.00202	0.0115	CcSEcCtD
Bosutinib—Nervous system disorder—Octreotide—thymus cancer	0.002	0.0114	CcSEcCtD
Bosutinib—Thrombocytopenia—Octreotide—thymus cancer	0.00199	0.0113	CcSEcCtD
Bosutinib—Skin disorder—Octreotide—thymus cancer	0.00198	0.0112	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Octreotide—thymus cancer	0.00186	0.0105	CcSEcCtD
Bosutinib—Dyspnoea—Octreotide—thymus cancer	0.00182	0.0103	CcSEcCtD
Bosutinib—Decreased appetite—Octreotide—thymus cancer	0.00177	0.0101	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Octreotide—thymus cancer	0.00176	0.00999	CcSEcCtD
Bosutinib—Fatigue—Octreotide—thymus cancer	0.00176	0.00998	CcSEcCtD
Bosutinib—Pain—Octreotide—thymus cancer	0.00174	0.0099	CcSEcCtD
Bosutinib—Feeling abnormal—Octreotide—thymus cancer	0.00168	0.00954	CcSEcCtD
Bosutinib—Gastrointestinal pain—Octreotide—thymus cancer	0.00167	0.00947	CcSEcCtD
Bosutinib—Urticaria—Octreotide—thymus cancer	0.00162	0.0092	CcSEcCtD
Bosutinib—Abdominal pain—Octreotide—thymus cancer	0.00161	0.00915	CcSEcCtD
Bosutinib—Body temperature increased—Octreotide—thymus cancer	0.00161	0.00915	CcSEcCtD
Bosutinib—Asthenia—Octreotide—thymus cancer	0.00146	0.00831	CcSEcCtD
Bosutinib—Pruritus—Octreotide—thymus cancer	0.00144	0.00819	CcSEcCtD
Bosutinib—Diarrhoea—Octreotide—thymus cancer	0.00139	0.00792	CcSEcCtD
Bosutinib—Dizziness—Octreotide—thymus cancer	0.00135	0.00766	CcSEcCtD
Bosutinib—Vomiting—Octreotide—thymus cancer	0.0013	0.00736	CcSEcCtD
Bosutinib—Rash—Octreotide—thymus cancer	0.00128	0.0073	CcSEcCtD
Bosutinib—Dermatitis—Octreotide—thymus cancer	0.00128	0.00729	CcSEcCtD
Bosutinib—Headache—Octreotide—thymus cancer	0.00128	0.00725	CcSEcCtD
Bosutinib—Nausea—Octreotide—thymus cancer	0.00121	0.00688	CcSEcCtD
Bosutinib—CLK1—thyroid gland—thymus cancer	0.000682	0.00154	CbGeAlD
Bosutinib—HCK—thyroid gland—thymus cancer	0.000682	0.00154	CbGeAlD
Bosutinib—RPS6KB1—cardiac atrium—thymus cancer	0.00068	0.00154	CbGeAlD
Bosutinib—BMPR2—lung—thymus cancer	0.000679	0.00154	CbGeAlD
Bosutinib—ABL2—thyroid gland—thymus cancer	0.000677	0.00153	CbGeAlD
Bosutinib—TXK—lymph node—thymus cancer	0.000677	0.00153	CbGeAlD
Bosutinib—ERBB3—lymphoid tissue—thymus cancer	0.000675	0.00153	CbGeAlD
Bosutinib—MAP2K2—lymphoid tissue—thymus cancer	0.000674	0.00153	CbGeAlD
Bosutinib—STK36—lung—thymus cancer	0.000674	0.00153	CbGeAlD
Bosutinib—EPHB3—lung—thymus cancer	0.000674	0.00153	CbGeAlD
Bosutinib—AXL—cardiac atrium—thymus cancer	0.000673	0.00152	CbGeAlD
Bosutinib—CAMK2G—bone marrow—thymus cancer	0.000671	0.00152	CbGeAlD
Bosutinib—BMP2K—bone marrow—thymus cancer	0.000671	0.00152	CbGeAlD
Bosutinib—FES—lymph node—thymus cancer	0.00067	0.00152	CbGeAlD
Bosutinib—VRK2—lymph node—thymus cancer	0.00067	0.00152	CbGeAlD
Bosutinib—CAMK2G—thyroid gland—thymus cancer	0.000669	0.00151	CbGeAlD
Bosutinib—BMP2K—thyroid gland—thymus cancer	0.000669	0.00151	CbGeAlD
Bosutinib—MAP3K2—lymphoid tissue—thymus cancer	0.000669	0.00151	CbGeAlD
Bosutinib—MERTK—lung—thymus cancer	0.000666	0.00151	CbGeAlD
Bosutinib—LRRK2—bone marrow—thymus cancer	0.000665	0.0015	CbGeAlD
Bosutinib—RPS6KB1—pituitary gland—thymus cancer	0.000664	0.0015	CbGeAlD
Bosutinib—LRRK2—thyroid gland—thymus cancer	0.000663	0.0015	CbGeAlD
Bosutinib—EGFR—thyroid gland—thymus cancer	0.000661	0.0015	CbGeAlD
Bosutinib—FGR—pituitary gland—thymus cancer	0.00066	0.00149	CbGeAlD
Bosutinib—SRC—epithelium—thymus cancer	0.000658	0.00149	CbGeAlD
Bosutinib—AXL—pituitary gland—thymus cancer	0.000657	0.00149	CbGeAlD
Bosutinib—SYK—lymph node—thymus cancer	0.000657	0.00149	CbGeAlD
Bosutinib—TNIK—lymph node—thymus cancer	0.000657	0.00149	CbGeAlD
Bosutinib—TBK1—lymphoid tissue—thymus cancer	0.000655	0.00148	CbGeAlD
Bosutinib—PTK2—lymphoid tissue—thymus cancer	0.000655	0.00148	CbGeAlD
Bosutinib—MAP4K4—lung—thymus cancer	0.000654	0.00148	CbGeAlD
Bosutinib—CDK2—lymph node—thymus cancer	0.000651	0.00147	CbGeAlD
Bosutinib—NUAK2—lung—thymus cancer	0.000649	0.00147	CbGeAlD
Bosutinib—BCR—lung—thymus cancer	0.000649	0.00147	CbGeAlD
Bosutinib—PTK2B—bone marrow—thymus cancer	0.000648	0.00147	CbGeAlD
Bosutinib—SLK—cardiac atrium—thymus cancer	0.000648	0.00147	CbGeAlD
Bosutinib—CSF1R—hematopoietic system—thymus cancer	0.000646	0.00146	CbGeAlD
Bosutinib—PTK2B—thyroid gland—thymus cancer	0.000646	0.00146	CbGeAlD
Bosutinib—STK26—lymph node—thymus cancer	0.000645	0.00146	CbGeAlD
Bosutinib—MAP3K12—lung—thymus cancer	0.000644	0.00146	CbGeAlD
Bosutinib—EPHB4—cardiac atrium—thymus cancer	0.000643	0.00146	CbGeAlD
Bosutinib—CSNK1E—thyroid gland—thymus cancer	0.000636	0.00144	CbGeAlD
Bosutinib—SLK—pituitary gland—thymus cancer	0.000633	0.00143	CbGeAlD
Bosutinib—STK35—lung—thymus cancer	0.000631	0.00143	CbGeAlD
Bosutinib—MAP2K1—lung—thymus cancer	0.000631	0.00143	CbGeAlD
Bosutinib—EPHA2—cardiac atrium—thymus cancer	0.000631	0.00143	CbGeAlD
Bosutinib—RPS6KB1—lymphoid tissue—thymus cancer	0.00063	0.00143	CbGeAlD
Bosutinib—FYN—cardiac atrium—thymus cancer	0.00063	0.00143	CbGeAlD
Bosutinib—EPHB4—pituitary gland—thymus cancer	0.000628	0.00142	CbGeAlD
Bosutinib—SIK1—bone marrow—thymus cancer	0.000627	0.00142	CbGeAlD
Bosutinib—IRAK4—bone marrow—thymus cancer	0.000627	0.00142	CbGeAlD
Bosutinib—CSK—lung—thymus cancer	0.000627	0.00142	CbGeAlD
Bosutinib—FGR—lymphoid tissue—thymus cancer	0.000626	0.00142	CbGeAlD
Bosutinib—SIK1—thyroid gland—thymus cancer	0.000626	0.00142	CbGeAlD
Bosutinib—IRAK4—thyroid gland—thymus cancer	0.000626	0.00142	CbGeAlD
Bosutinib—AXL—lymphoid tissue—thymus cancer	0.000624	0.00141	CbGeAlD
Bosutinib—CSNK1A1—lung—thymus cancer	0.000623	0.00141	CbGeAlD
Bosutinib—CHEK2—lymph node—thymus cancer	0.000623	0.00141	CbGeAlD
Bosutinib—EPHA4—thyroid gland—thymus cancer	0.000619	0.0014	CbGeAlD
Bosutinib—HCK—lung—thymus cancer	0.000619	0.0014	CbGeAlD
Bosutinib—CLK1—lung—thymus cancer	0.000619	0.0014	CbGeAlD
Bosutinib—WEE1—lymph node—thymus cancer	0.000618	0.0014	CbGeAlD
Bosutinib—DMPK—lymph node—thymus cancer	0.000618	0.0014	CbGeAlD
Bosutinib—EPHA2—pituitary gland—thymus cancer	0.000616	0.0014	CbGeAlD
Bosutinib—MAP3K3—cardiac atrium—thymus cancer	0.000615	0.00139	CbGeAlD
Bosutinib—MAP4K5—cardiac atrium—thymus cancer	0.000615	0.00139	CbGeAlD
Bosutinib—ABL2—lung—thymus cancer	0.000615	0.00139	CbGeAlD
Bosutinib—FYN—pituitary gland—thymus cancer	0.000615	0.00139	CbGeAlD
Bosutinib—MAP2K2—bone marrow—thymus cancer	0.000613	0.00139	CbGeAlD
Bosutinib—ULK3—bone marrow—thymus cancer	0.000613	0.00139	CbGeAlD
Bosutinib—ERBB3—thyroid gland—thymus cancer	0.000613	0.00139	CbGeAlD
Bosutinib—ULK3—thyroid gland—thymus cancer	0.000612	0.00139	CbGeAlD
Bosutinib—MAP2K2—thyroid gland—thymus cancer	0.000612	0.00139	CbGeAlD
Bosutinib—MAP3K2—bone marrow—thymus cancer	0.000609	0.00138	CbGeAlD
Bosutinib—BMP2K—lung—thymus cancer	0.000608	0.00138	CbGeAlD
Bosutinib—CAMK2G—lung—thymus cancer	0.000608	0.00138	CbGeAlD
Bosutinib—MAP3K2—thyroid gland—thymus cancer	0.000607	0.00138	CbGeAlD
Bosutinib—MAP3K7—bone marrow—thymus cancer	0.000603	0.00137	CbGeAlD
Bosutinib—LRRK2—lung—thymus cancer	0.000602	0.00136	CbGeAlD
Bosutinib—MAP3K7—thyroid gland—thymus cancer	0.000602	0.00136	CbGeAlD
Bosutinib—MAP4K5—pituitary gland—thymus cancer	0.000601	0.00136	CbGeAlD
Bosutinib—MAP3K3—pituitary gland—thymus cancer	0.000601	0.00136	CbGeAlD
Bosutinib—EGFR—lung—thymus cancer	0.0006	0.00136	CbGeAlD
Bosutinib—TBK1—bone marrow—thymus cancer	0.000596	0.00135	CbGeAlD
Bosutinib—TBK1—thyroid gland—thymus cancer	0.000595	0.00135	CbGeAlD
Bosutinib—PTK2—thyroid gland—thymus cancer	0.000595	0.00135	CbGeAlD
Bosutinib—STK25—lymph node—thymus cancer	0.00059	0.00134	CbGeAlD
Bosutinib—PTK2B—lung—thymus cancer	0.000587	0.00133	CbGeAlD
Bosutinib—EPHA3—lymph node—thymus cancer	0.000586	0.00133	CbGeAlD
Bosutinib—EPHA2—lymphoid tissue—thymus cancer	0.000585	0.00132	CbGeAlD
Bosutinib—IRAK1—bone marrow—thymus cancer	0.000585	0.00132	CbGeAlD
Bosutinib—FYN—lymphoid tissue—thymus cancer	0.000584	0.00132	CbGeAlD
Bosutinib—IRAK1—thyroid gland—thymus cancer	0.000583	0.00132	CbGeAlD
Bosutinib—CSNK1E—lung—thymus cancer	0.000577	0.00131	CbGeAlD
Bosutinib—RPS6KB1—bone marrow—thymus cancer	0.000574	0.0013	CbGeAlD
Bosutinib—PLK2—lymph node—thymus cancer	0.000574	0.0013	CbGeAlD
Bosutinib—PDGFRB—hematopoietic system—thymus cancer	0.000573	0.0013	CbGeAlD
Bosutinib—RPS6KB1—thyroid gland—thymus cancer	0.000572	0.0013	CbGeAlD
Bosutinib—MAP4K5—lymphoid tissue—thymus cancer	0.000571	0.00129	CbGeAlD
Bosutinib—LCK—bone marrow—thymus cancer	0.00057	0.00129	CbGeAlD
Bosutinib—FGR—bone marrow—thymus cancer	0.00057	0.00129	CbGeAlD
Bosutinib—SIK3—lymph node—thymus cancer	0.00057	0.00129	CbGeAlD
Bosutinib—FGR—thyroid gland—thymus cancer	0.000569	0.00129	CbGeAlD
Bosutinib—LCK—thyroid gland—thymus cancer	0.000569	0.00129	CbGeAlD
Bosutinib—SIK1—lung—thymus cancer	0.000568	0.00129	CbGeAlD
Bosutinib—IRAK4—lung—thymus cancer	0.000568	0.00129	CbGeAlD
Bosutinib—YES1—cardiac atrium—thymus cancer	0.000568	0.00129	CbGeAlD
Bosutinib—AXL—thyroid gland—thymus cancer	0.000567	0.00128	CbGeAlD
Bosutinib—EPHA4—lung—thymus cancer	0.000563	0.00127	CbGeAlD
Bosutinib—TAOK3—cardiac atrium—thymus cancer	0.000561	0.00127	CbGeAlD
Bosutinib—ERBB3—lung—thymus cancer	0.000557	0.00126	CbGeAlD
Bosutinib—ULK3—lung—thymus cancer	0.000556	0.00126	CbGeAlD
Bosutinib—MAP2K2—lung—thymus cancer	0.000556	0.00126	CbGeAlD
Bosutinib—YES1—pituitary gland—thymus cancer	0.000555	0.00126	CbGeAlD
Bosutinib—MAP3K2—lung—thymus cancer	0.000552	0.00125	CbGeAlD
Bosutinib—STK4—lymph node—thymus cancer	0.000548	0.00124	CbGeAlD
Bosutinib—TAOK3—pituitary gland—thymus cancer	0.000548	0.00124	CbGeAlD
Bosutinib—SLK—bone marrow—thymus cancer	0.000547	0.00124	CbGeAlD
Bosutinib—SRC—cardiac atrium—thymus cancer	0.000547	0.00124	CbGeAlD
Bosutinib—MAP3K7—lung—thymus cancer	0.000547	0.00124	CbGeAlD
Bosutinib—SLK—thyroid gland—thymus cancer	0.000545	0.00123	CbGeAlD
Bosutinib—EPHB4—bone marrow—thymus cancer	0.000543	0.00123	CbGeAlD
Bosutinib—CAMK1D—lymph node—thymus cancer	0.000542	0.00123	CbGeAlD
Bosutinib—EPHB4—thyroid gland—thymus cancer	0.000541	0.00123	CbGeAlD
Bosutinib—PTK2—lung—thymus cancer	0.00054	0.00122	CbGeAlD
Bosutinib—TBK1—lung—thymus cancer	0.00054	0.00122	CbGeAlD
Bosutinib—STK24—lymph node—thymus cancer	0.000536	0.00121	CbGeAlD
Bosutinib—FYN—bone marrow—thymus cancer	0.000532	0.0012	CbGeAlD
Bosutinib—EPHA2—thyroid gland—thymus cancer	0.000531	0.0012	CbGeAlD
Bosutinib—FYN—thyroid gland—thymus cancer	0.00053	0.0012	CbGeAlD
Bosutinib—IRAK1—lung—thymus cancer	0.00053	0.0012	CbGeAlD
Bosutinib—YES1—lymphoid tissue—thymus cancer	0.000527	0.00119	CbGeAlD
Bosutinib—PDGFRB—epithelium—thymus cancer	0.000524	0.00119	CbGeAlD
Bosutinib—STK10—lymphoid tissue—thymus cancer	0.000522	0.00118	CbGeAlD
Bosutinib—TAOK3—lymphoid tissue—thymus cancer	0.00052	0.00118	CbGeAlD
Bosutinib—RPS6KB1—lung—thymus cancer	0.00052	0.00118	CbGeAlD
Bosutinib—MAP4K5—bone marrow—thymus cancer	0.000519	0.00118	CbGeAlD
Bosutinib—MAP3K3—bone marrow—thymus cancer	0.000519	0.00118	CbGeAlD
Bosutinib—FER—lymph node—thymus cancer	0.000518	0.00117	CbGeAlD
Bosutinib—ALK—lymph node—thymus cancer	0.000518	0.00117	CbGeAlD
Bosutinib—MAP4K5—thyroid gland—thymus cancer	0.000518	0.00117	CbGeAlD
Bosutinib—MAP3K3—thyroid gland—thymus cancer	0.000518	0.00117	CbGeAlD
Bosutinib—FGR—lung—thymus cancer	0.000517	0.00117	CbGeAlD
Bosutinib—LCK—lung—thymus cancer	0.000517	0.00117	CbGeAlD
Bosutinib—AXL—lung—thymus cancer	0.000515	0.00117	CbGeAlD
Bosutinib—ABL1—hematopoietic system—thymus cancer	0.000511	0.00116	CbGeAlD
Bosutinib—MAP4K1—lymph node—thymus cancer	0.000508	0.00115	CbGeAlD
Bosutinib—SRC—lymphoid tissue—thymus cancer	0.000507	0.00115	CbGeAlD
Bosutinib—BTK—lymph node—thymus cancer	0.000505	0.00114	CbGeAlD
Bosutinib—MAP2K5—cardiac atrium—thymus cancer	0.000503	0.00114	CbGeAlD
Bosutinib—TNK2—lymph node—thymus cancer	0.000498	0.00113	CbGeAlD
Bosutinib—SLK—lung—thymus cancer	0.000495	0.00112	CbGeAlD
Bosutinib—EPHB4—lung—thymus cancer	0.000492	0.00111	CbGeAlD
Bosutinib—MAP2K5—pituitary gland—thymus cancer	0.000491	0.00111	CbGeAlD
Bosutinib—MAP4K2—lymph node—thymus cancer	0.000491	0.00111	CbGeAlD
Bosutinib—CSF1R—cardiac atrium—thymus cancer	0.000491	0.00111	CbGeAlD
Bosutinib—STK3—lymph node—thymus cancer	0.000484	0.0011	CbGeAlD
Bosutinib—EPHA2—lung—thymus cancer	0.000482	0.00109	CbGeAlD
Bosutinib—FYN—lung—thymus cancer	0.000482	0.00109	CbGeAlD
Bosutinib—YES1—bone marrow—thymus cancer	0.00048	0.00109	CbGeAlD
Bosutinib—CSF1R—pituitary gland—thymus cancer	0.000479	0.00109	CbGeAlD
Bosutinib—YES1—thyroid gland—thymus cancer	0.000479	0.00108	CbGeAlD
Bosutinib—STK10—bone marrow—thymus cancer	0.000475	0.00108	CbGeAlD
Bosutinib—STK10—thyroid gland—thymus cancer	0.000474	0.00107	CbGeAlD
Bosutinib—TAOK3—bone marrow—thymus cancer	0.000474	0.00107	CbGeAlD
Bosutinib—TAOK3—thyroid gland—thymus cancer	0.000472	0.00107	CbGeAlD
Bosutinib—MAP3K3—lung—thymus cancer	0.000471	0.00107	CbGeAlD
Bosutinib—MAP4K5—lung—thymus cancer	0.000471	0.00107	CbGeAlD
Bosutinib—BMPR2—lymph node—thymus cancer	0.000464	0.00105	CbGeAlD
Bosutinib—EPHB3—lymph node—thymus cancer	0.000461	0.00104	CbGeAlD
Bosutinib—STK36—lymph node—thymus cancer	0.000461	0.00104	CbGeAlD
Bosutinib—SRC—thyroid gland—thymus cancer	0.00046	0.00104	CbGeAlD
Bosutinib—MERTK—lymph node—thymus cancer	0.000455	0.00103	CbGeAlD
Bosutinib—CSF1R—lymphoid tissue—thymus cancer	0.000455	0.00103	CbGeAlD
Bosutinib—MAP4K4—lymph node—thymus cancer	0.000447	0.00101	CbGeAlD
Bosutinib—BCR—lymph node—thymus cancer	0.000444	0.001	CbGeAlD
Bosutinib—NUAK2—lymph node—thymus cancer	0.000444	0.001	CbGeAlD
Bosutinib—MAP3K12—lymph node—thymus cancer	0.000441	0.000998	CbGeAlD
Bosutinib—PDGFRB—cardiac atrium—thymus cancer	0.000435	0.000985	CbGeAlD
Bosutinib—YES1—lung—thymus cancer	0.000435	0.000984	CbGeAlD
Bosutinib—STK35—lymph node—thymus cancer	0.000432	0.000977	CbGeAlD
Bosutinib—MAP2K1—lymph node—thymus cancer	0.000432	0.000977	CbGeAlD
Bosutinib—STK10—lung—thymus cancer	0.000431	0.000975	CbGeAlD
Bosutinib—TAOK3—lung—thymus cancer	0.000429	0.000971	CbGeAlD
Bosutinib—CSK—lymph node—thymus cancer	0.000429	0.000971	CbGeAlD
Bosutinib—CSNK1A1—lymph node—thymus cancer	0.000426	0.000965	CbGeAlD
Bosutinib—PDGFRB—pituitary gland—thymus cancer	0.000425	0.000963	CbGeAlD
Bosutinib—MAP2K5—thyroid gland—thymus cancer	0.000424	0.000959	CbGeAlD
Bosutinib—HCK—lymph node—thymus cancer	0.000423	0.000959	CbGeAlD
Bosutinib—CLK1—lymph node—thymus cancer	0.000423	0.000959	CbGeAlD
Bosutinib—ABL2—lymph node—thymus cancer	0.000421	0.000953	CbGeAlD
Bosutinib—SRC—lung—thymus cancer	0.000418	0.000947	CbGeAlD
Bosutinib—CAMK2G—lymph node—thymus cancer	0.000416	0.000941	CbGeAlD
Bosutinib—BMP2K—lymph node—thymus cancer	0.000416	0.000941	CbGeAlD
Bosutinib—CSF1R—bone marrow—thymus cancer	0.000414	0.000938	CbGeAlD
Bosutinib—CSF1R—thyroid gland—thymus cancer	0.000413	0.000936	CbGeAlD
Bosutinib—LRRK2—lymph node—thymus cancer	0.000412	0.000932	CbGeAlD
Bosutinib—EGFR—lymph node—thymus cancer	0.000411	0.00093	CbGeAlD
Bosutinib—PDGFRB—lymphoid tissue—thymus cancer	0.000404	0.000914	CbGeAlD
Bosutinib—PTK2B—lymph node—thymus cancer	0.000401	0.000909	CbGeAlD
Bosutinib—CSNK1E—lymph node—thymus cancer	0.000395	0.000894	CbGeAlD
Bosutinib—SIK1—lymph node—thymus cancer	0.000389	0.00088	CbGeAlD
Bosutinib—IRAK4—lymph node—thymus cancer	0.000389	0.00088	CbGeAlD
Bosutinib—ABL1—cardiac atrium—thymus cancer	0.000388	0.000878	CbGeAlD
Bosutinib—EPHA4—lymph node—thymus cancer	0.000385	0.000871	CbGeAlD
Bosutinib—MAP2K5—lung—thymus cancer	0.000385	0.000871	CbGeAlD
Bosutinib—ERBB3—lymph node—thymus cancer	0.000381	0.000863	CbGeAlD
Bosutinib—MAP2K2—lymph node—thymus cancer	0.00038	0.000861	CbGeAlD
Bosutinib—ULK3—lymph node—thymus cancer	0.00038	0.000861	CbGeAlD
Bosutinib—ABL1—pituitary gland—thymus cancer	0.000379	0.000858	CbGeAlD
Bosutinib—MAP3K2—lymph node—thymus cancer	0.000377	0.000854	CbGeAlD
Bosutinib—CSF1R—lung—thymus cancer	0.000375	0.00085	CbGeAlD
Bosutinib—MAP3K7—lymph node—thymus cancer	0.000374	0.000846	CbGeAlD
Bosutinib—TBK1—lymph node—thymus cancer	0.00037	0.000837	CbGeAlD
Bosutinib—PTK2—lymph node—thymus cancer	0.00037	0.000837	CbGeAlD
Bosutinib—PDGFRB—bone marrow—thymus cancer	0.000367	0.000832	CbGeAlD
Bosutinib—PDGFRB—thyroid gland—thymus cancer	0.000367	0.00083	CbGeAlD
Bosutinib—IRAK1—lymph node—thymus cancer	0.000362	0.00082	CbGeAlD
Bosutinib—ABL1—lymphoid tissue—thymus cancer	0.00036	0.000814	CbGeAlD
Bosutinib—RPS6KB1—lymph node—thymus cancer	0.000356	0.000805	CbGeAlD
Bosutinib—LCK—lymph node—thymus cancer	0.000353	0.0008	CbGeAlD
Bosutinib—FGR—lymph node—thymus cancer	0.000353	0.0008	CbGeAlD
Bosutinib—AXL—lymph node—thymus cancer	0.000352	0.000797	CbGeAlD
Bosutinib—SLK—lymph node—thymus cancer	0.000339	0.000767	CbGeAlD
Bosutinib—EPHB4—lymph node—thymus cancer	0.000336	0.000762	CbGeAlD
Bosutinib—PDGFRB—lung—thymus cancer	0.000333	0.000754	CbGeAlD
Bosutinib—EPHA2—lymph node—thymus cancer	0.00033	0.000747	CbGeAlD
Bosutinib—FYN—lymph node—thymus cancer	0.000329	0.000746	CbGeAlD
Bosutinib—ABL1—bone marrow—thymus cancer	0.000328	0.000742	CbGeAlD
Bosutinib—ABL1—thyroid gland—thymus cancer	0.000327	0.00074	CbGeAlD
Bosutinib—MAP3K3—lymph node—thymus cancer	0.000322	0.000729	CbGeAlD
Bosutinib—MAP4K5—lymph node—thymus cancer	0.000322	0.000729	CbGeAlD
Bosutinib—YES1—lymph node—thymus cancer	0.000297	0.000673	CbGeAlD
Bosutinib—ABL1—lung—thymus cancer	0.000297	0.000672	CbGeAlD
Bosutinib—STK10—lymph node—thymus cancer	0.000295	0.000667	CbGeAlD
Bosutinib—TAOK3—lymph node—thymus cancer	0.000293	0.000664	CbGeAlD
Bosutinib—SRC—lymph node—thymus cancer	0.000286	0.000647	CbGeAlD
Bosutinib—MAP2K5—lymph node—thymus cancer	0.000263	0.000596	CbGeAlD
Bosutinib—CSF1R—lymph node—thymus cancer	0.000257	0.000581	CbGeAlD
Bosutinib—PDGFRB—lymph node—thymus cancer	0.000228	0.000516	CbGeAlD
Bosutinib—CYP3A4—hematopoietic system—thymus cancer	0.000224	0.000508	CbGeAlD
Bosutinib—ABL1—lymph node—thymus cancer	0.000203	0.000459	CbGeAlD
Bosutinib—ABCB1—hematopoietic system—thymus cancer	0.000159	0.00036	CbGeAlD
Bosutinib—ABCB1—epithelium—thymus cancer	0.000145	0.000329	CbGeAlD
Bosutinib—ABCB1—pituitary gland—thymus cancer	0.000118	0.000267	CbGeAlD
Bosutinib—ABCB1—lymphoid tissue—thymus cancer	0.000112	0.000253	CbGeAlD
Bosutinib—ABCB1—bone marrow—thymus cancer	0.000102	0.000231	CbGeAlD
Bosutinib—ABCB1—thyroid gland—thymus cancer	0.000102	0.00023	CbGeAlD
Bosutinib—ABCB1—lung—thymus cancer	9.23e-05	0.000209	CbGeAlD
Bosutinib—ABCB1—lymph node—thymus cancer	6.31e-05	0.000143	CbGeAlD
Bosutinib—LCK—Innate Immune System—CD4—thymus cancer	2.76e-05	7.21e-05	CbGpPWpGaD
Bosutinib—ERBB3—Immune System—IL2—thymus cancer	2.76e-05	7.21e-05	CbGpPWpGaD
Bosutinib—EGFR—Adaptive Immune System—CD4—thymus cancer	2.75e-05	7.19e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—KIT—thymus cancer	2.73e-05	7.13e-05	CbGpPWpGaD
Bosutinib—BLK—Adaptive Immune System—AKT1—thymus cancer	2.69e-05	7.03e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—KIT—thymus cancer	2.68e-05	7.01e-05	CbGpPWpGaD
Bosutinib—PTK2—Immune System—CD4—thymus cancer	2.67e-05	6.97e-05	CbGpPWpGaD
Bosutinib—BMPR2—Signaling Pathways—TP53—thymus cancer	2.66e-05	6.95e-05	CbGpPWpGaD
Bosutinib—PRKCQ—Signaling by GPCR—AKT1—thymus cancer	2.66e-05	6.95e-05	CbGpPWpGaD
Bosutinib—LCK—Adaptive Immune System—CD4—thymus cancer	2.65e-05	6.93e-05	CbGpPWpGaD
Bosutinib—YES1—Immune System—CD4—thymus cancer	2.63e-05	6.87e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—KIT—thymus cancer	2.63e-05	6.87e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—KIT—thymus cancer	2.63e-05	6.87e-05	CbGpPWpGaD
Bosutinib—SRC—Platelet activation, signaling and aggregation—AKT1—thymus cancer	2.63e-05	6.87e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—KIT—thymus cancer	2.62e-05	6.85e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MAML2—thymus cancer	2.6e-05	6.81e-05	CbGpPWpGaD
Bosutinib—PTK2—Developmental Biology—AKT1—thymus cancer	2.59e-05	6.76e-05	CbGpPWpGaD
Bosutinib—ERBB3—Innate Immune System—AKT1—thymus cancer	2.56e-05	6.71e-05	CbGpPWpGaD
Bosutinib—LYN—Immune System—KIT—thymus cancer	2.56e-05	6.7e-05	CbGpPWpGaD
Bosutinib—ABL1—Immune System—KIT—thymus cancer	2.55e-05	6.67e-05	CbGpPWpGaD
Bosutinib—YES1—Developmental Biology—AKT1—thymus cancer	2.55e-05	6.67e-05	CbGpPWpGaD
Bosutinib—BCR—Signaling Pathways—TP53—thymus cancer	2.55e-05	6.66e-05	CbGpPWpGaD
Bosutinib—PTK2—Hemostasis—AKT1—thymus cancer	2.54e-05	6.63e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—KIT—thymus cancer	2.53e-05	6.62e-05	CbGpPWpGaD
Bosutinib—FYN—Immune System—KIT—thymus cancer	2.52e-05	6.6e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—KIT—thymus cancer	2.51e-05	6.56e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling by NGF—AKT1—thymus cancer	2.5e-05	6.55e-05	CbGpPWpGaD
Bosutinib—YES1—Hemostasis—AKT1—thymus cancer	2.5e-05	6.54e-05	CbGpPWpGaD
Bosutinib—SRC—Hemostasis—IL2—thymus cancer	2.5e-05	6.53e-05	CbGpPWpGaD
Bosutinib—IRAK1—Immune System—CD4—thymus cancer	2.49e-05	6.52e-05	CbGpPWpGaD
Bosutinib—FER—Signaling Pathways—AKT1—thymus cancer	2.48e-05	6.49e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—KIT—thymus cancer	2.48e-05	6.48e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—CD8A—thymus cancer	2.48e-05	6.48e-05	CbGpPWpGaD
Bosutinib—SYK—Immune System—AKT1—thymus cancer	2.47e-05	6.47e-05	CbGpPWpGaD
Bosutinib—ERBB3—Adaptive Immune System—AKT1—thymus cancer	2.46e-05	6.44e-05	CbGpPWpGaD
Bosutinib—PTK2—Immune System—IL2—thymus cancer	2.45e-05	6.41e-05	CbGpPWpGaD
Bosutinib—SRC—Innate Immune System—CD4—thymus cancer	2.44e-05	6.39e-05	CbGpPWpGaD
Bosutinib—PRKCQ—Immune System—AKT1—thymus cancer	2.43e-05	6.35e-05	CbGpPWpGaD
Bosutinib—YES1—Immune System—IL2—thymus cancer	2.42e-05	6.32e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—KIT—thymus cancer	2.42e-05	6.32e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling by NGF—AKT1—thymus cancer	2.41e-05	6.31e-05	CbGpPWpGaD
Bosutinib—AXL—Signaling Pathways—AKT1—thymus cancer	2.35e-05	6.15e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—CD4—thymus cancer	2.35e-05	6.14e-05	CbGpPWpGaD
Bosutinib—SRC—Adaptive Immune System—CD4—thymus cancer	2.34e-05	6.13e-05	CbGpPWpGaD
Bosutinib—CSK—Immune System—AKT1—thymus cancer	2.34e-05	6.13e-05	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—IL2—thymus cancer	2.34e-05	6.11e-05	CbGpPWpGaD
Bosutinib—FYN—Disease—KIT—thymus cancer	2.33e-05	6.09e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—KIT—thymus cancer	2.32e-05	6.06e-05	CbGpPWpGaD
Bosutinib—IRAK1—Immune System—IL2—thymus cancer	2.29e-05	6e-05	CbGpPWpGaD
Bosutinib—PTK2—Innate Immune System—AKT1—thymus cancer	2.28e-05	5.97e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—KIT—thymus cancer	2.25e-05	5.89e-05	CbGpPWpGaD
Bosutinib—YES1—Innate Immune System—AKT1—thymus cancer	2.25e-05	5.89e-05	CbGpPWpGaD
Bosutinib—BMPR2—Signaling Pathways—AKT1—thymus cancer	2.24e-05	5.87e-05	CbGpPWpGaD
Bosutinib—PRKCQ—Disease—AKT1—thymus cancer	2.24e-05	5.86e-05	CbGpPWpGaD
Bosutinib—CSNK1A1—Disease—AKT1—thymus cancer	2.24e-05	5.86e-05	CbGpPWpGaD
Bosutinib—FES—Signaling Pathways—TP53—thymus cancer	2.23e-05	5.82e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—KIT—thymus cancer	2.22e-05	5.81e-05	CbGpPWpGaD
Bosutinib—LYN—Hemostasis—TP53—thymus cancer	2.21e-05	5.78e-05	CbGpPWpGaD
Bosutinib—ABL1—Hemostasis—TP53—thymus cancer	2.2e-05	5.75e-05	CbGpPWpGaD
Bosutinib—EGFR—Immune System—KIT—thymus cancer	2.18e-05	5.7e-05	CbGpPWpGaD
Bosutinib—FYN—Hemostasis—TP53—thymus cancer	2.17e-05	5.69e-05	CbGpPWpGaD
Bosutinib—CSK—Disease—AKT1—thymus cancer	2.16e-05	5.66e-05	CbGpPWpGaD
Bosutinib—YES1—Adaptive Immune System—AKT1—thymus cancer	2.16e-05	5.65e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—IL2—thymus cancer	2.16e-05	5.65e-05	CbGpPWpGaD
Bosutinib—BCR—Signaling Pathways—AKT1—thymus cancer	2.15e-05	5.63e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling by NGF—AKT1—thymus cancer	2.14e-05	5.59e-05	CbGpPWpGaD
Bosutinib—IRAK1—Innate Immune System—AKT1—thymus cancer	2.14e-05	5.58e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—KIT—thymus cancer	2.11e-05	5.51e-05	CbGpPWpGaD
Bosutinib—TBK1—Immune System—AKT1—thymus cancer	2.1e-05	5.5e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—KIT—thymus cancer	2.1e-05	5.49e-05	CbGpPWpGaD
Bosutinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—thymus cancer	2.07e-05	5.41e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling by GPCR—IL2—thymus cancer	2.07e-05	5.4e-05	CbGpPWpGaD
Bosutinib—CAMK2G—Immune System—AKT1—thymus cancer	2.06e-05	5.4e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—CD4—thymus cancer	2.05e-05	5.36e-05	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—IL2—thymus cancer	2.02e-05	5.28e-05	CbGpPWpGaD
Bosutinib—MAP3K3—Immune System—AKT1—thymus cancer	2.02e-05	5.27e-05	CbGpPWpGaD
Bosutinib—EGFR—Disease—KIT—thymus cancer	2.01e-05	5.26e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Innate Immune System—AKT1—thymus cancer	2.01e-05	5.26e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—CD4—thymus cancer	2e-05	5.24e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—IL2—thymus cancer	1.99e-05	5.21e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Developmental Biology—AKT1—thymus cancer	1.99e-05	5.2e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—KIT—thymus cancer	1.98e-05	5.19e-05	CbGpPWpGaD
Bosutinib—BTK—Immune System—AKT1—thymus cancer	1.96e-05	5.13e-05	CbGpPWpGaD
Bosutinib—LYN—Immune System—CD4—thymus cancer	1.96e-05	5.13e-05	CbGpPWpGaD
Bosutinib—ABL1—Immune System—CD4—thymus cancer	1.95e-05	5.1e-05	CbGpPWpGaD
Bosutinib—LCK—Disease—KIT—thymus cancer	1.94e-05	5.07e-05	CbGpPWpGaD
Bosutinib—ROCK1—GPCR downstream signaling—AKT1—thymus cancer	1.94e-05	5.07e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—IL2—thymus cancer	1.93e-05	5.05e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Adaptive Immune System—AKT1—thymus cancer	1.93e-05	5.05e-05	CbGpPWpGaD
Bosutinib—FYN—Immune System—CD4—thymus cancer	1.93e-05	5.05e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—CD4—thymus cancer	1.92e-05	5.02e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—IL2—thymus cancer	1.92e-05	5.02e-05	CbGpPWpGaD
Bosutinib—LYN—Developmental Biology—AKT1—thymus cancer	1.9e-05	4.97e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—CD4—thymus cancer	1.89e-05	4.95e-05	CbGpPWpGaD
Bosutinib—SYK—Signaling Pathways—TP53—thymus cancer	1.89e-05	4.95e-05	CbGpPWpGaD
Bosutinib—ABL1—Developmental Biology—AKT1—thymus cancer	1.89e-05	4.95e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—IL2—thymus cancer	1.89e-05	4.94e-05	CbGpPWpGaD
Bosutinib—FES—Signaling Pathways—AKT1—thymus cancer	1.88e-05	4.92e-05	CbGpPWpGaD
Bosutinib—IRAK4—Immune System—AKT1—thymus cancer	1.87e-05	4.9e-05	CbGpPWpGaD
Bosutinib—FYN—Developmental Biology—AKT1—thymus cancer	1.87e-05	4.89e-05	CbGpPWpGaD
Bosutinib—LYN—Hemostasis—AKT1—thymus cancer	1.86e-05	4.88e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Developmental Biology—AKT1—thymus cancer	1.86e-05	4.87e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—KIT—thymus cancer	1.86e-05	4.86e-05	CbGpPWpGaD
Bosutinib—CSNK1A1—Signaling Pathways—TP53—thymus cancer	1.86e-05	4.86e-05	CbGpPWpGaD
Bosutinib—PRKCQ—Signaling Pathways—TP53—thymus cancer	1.86e-05	4.86e-05	CbGpPWpGaD
Bosutinib—ABL1—Hemostasis—AKT1—thymus cancer	1.86e-05	4.85e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—CD4—thymus cancer	1.85e-05	4.83e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—IL2—thymus cancer	1.85e-05	4.83e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—IL2—thymus cancer	1.85e-05	4.83e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—IL2—thymus cancer	1.84e-05	4.82e-05	CbGpPWpGaD
Bosutinib—FYN—Hemostasis—AKT1—thymus cancer	1.84e-05	4.8e-05	CbGpPWpGaD
Bosutinib—CSNK1E—Disease—AKT1—thymus cancer	1.81e-05	4.73e-05	CbGpPWpGaD
Bosutinib—LCK—Hemostasis—TP53—thymus cancer	1.81e-05	4.73e-05	CbGpPWpGaD
Bosutinib—LYN—Immune System—IL2—thymus cancer	1.8e-05	4.72e-05	CbGpPWpGaD
Bosutinib—HCK—Immune System—AKT1—thymus cancer	1.8e-05	4.71e-05	CbGpPWpGaD
Bosutinib—ABL1—Immune System—IL2—thymus cancer	1.79e-05	4.69e-05	CbGpPWpGaD
Bosutinib—CSK—Signaling Pathways—TP53—thymus cancer	1.79e-05	4.69e-05	CbGpPWpGaD
Bosutinib—FYN—Disease—CD4—thymus cancer	1.78e-05	4.66e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—IL2—thymus cancer	1.78e-05	4.66e-05	CbGpPWpGaD
Bosutinib—FYN—Immune System—IL2—thymus cancer	1.78e-05	4.64e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—CD4—thymus cancer	1.77e-05	4.63e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—IL2—thymus cancer	1.77e-05	4.62e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling by GPCR—AKT1—thymus cancer	1.76e-05	4.6e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Innate Immune System—AKT1—thymus cancer	1.76e-05	4.6e-05	CbGpPWpGaD
Bosutinib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—thymus cancer	1.75e-05	4.56e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—KIT—thymus cancer	1.73e-05	4.54e-05	CbGpPWpGaD
Bosutinib—SRC—Disease—KIT—thymus cancer	1.72e-05	4.49e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Innate Immune System—AKT1—thymus cancer	1.71e-05	4.48e-05	CbGpPWpGaD
Bosutinib—ERBB4—Immune System—AKT1—thymus cancer	1.69e-05	4.43e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—KIT—thymus cancer	1.69e-05	4.43e-05	CbGpPWpGaD
Bosutinib—LYN—Innate Immune System—AKT1—thymus cancer	1.68e-05	4.39e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—IL2—thymus cancer	1.68e-05	4.39e-05	CbGpPWpGaD
Bosutinib—ABL1—Innate Immune System—AKT1—thymus cancer	1.67e-05	4.37e-05	CbGpPWpGaD
Bosutinib—PTK2B—Immune System—AKT1—thymus cancer	1.67e-05	4.37e-05	CbGpPWpGaD
Bosutinib—EGFR—Immune System—CD4—thymus cancer	1.67e-05	4.36e-05	CbGpPWpGaD
Bosutinib—HCK—Disease—AKT1—thymus cancer	1.66e-05	4.34e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—KIT—thymus cancer	1.66e-05	4.33e-05	CbGpPWpGaD
Bosutinib—FYN—Innate Immune System—AKT1—thymus cancer	1.65e-05	4.32e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Adaptive Immune System—AKT1—thymus cancer	1.65e-05	4.31e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Innate Immune System—AKT1—thymus cancer	1.64e-05	4.3e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—KIT—thymus cancer	1.63e-05	4.27e-05	CbGpPWpGaD
Bosutinib—BLK—Immune System—AKT1—thymus cancer	1.63e-05	4.26e-05	CbGpPWpGaD
Bosutinib—FGR—Immune System—AKT1—thymus cancer	1.62e-05	4.25e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—KIT—thymus cancer	1.62e-05	4.24e-05	CbGpPWpGaD
Bosutinib—EGFR—Developmental Biology—AKT1—thymus cancer	1.62e-05	4.23e-05	CbGpPWpGaD
Bosutinib—LYN—Adaptive Immune System—AKT1—thymus cancer	1.61e-05	4.22e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—CD4—thymus cancer	1.61e-05	4.2e-05	CbGpPWpGaD
Bosutinib—SRC—Hemostasis—TP53—thymus cancer	1.6e-05	4.19e-05	CbGpPWpGaD
Bosutinib—SYK—Signaling Pathways—AKT1—thymus cancer	1.6e-05	4.18e-05	CbGpPWpGaD
Bosutinib—FYN—Adaptive Immune System—AKT1—thymus cancer	1.59e-05	4.15e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—IL2—thymus cancer	1.59e-05	4.15e-05	CbGpPWpGaD
Bosutinib—PRKCQ—Signaling Pathways—AKT1—thymus cancer	1.57e-05	4.1e-05	CbGpPWpGaD
Bosutinib—CSNK1A1—Signaling Pathways—AKT1—thymus cancer	1.57e-05	4.1e-05	CbGpPWpGaD
Bosutinib—ERBB4—Disease—AKT1—thymus cancer	1.56e-05	4.09e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—IL2—thymus cancer	1.56e-05	4.09e-05	CbGpPWpGaD
Bosutinib—EGFR—Disease—CD4—thymus cancer	1.54e-05	4.03e-05	CbGpPWpGaD
Bosutinib—EGFR—Immune System—IL2—thymus cancer	1.53e-05	4.01e-05	CbGpPWpGaD
Bosutinib—LCK—Hemostasis—AKT1—thymus cancer	1.53e-05	4e-05	CbGpPWpGaD
Bosutinib—CSK—Signaling Pathways—AKT1—thymus cancer	1.52e-05	3.96e-05	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—TP53—thymus cancer	1.5e-05	3.93e-05	CbGpPWpGaD
Bosutinib—ERBB3—Immune System—AKT1—thymus cancer	1.49e-05	3.91e-05	CbGpPWpGaD
Bosutinib—LCK—Disease—CD4—thymus cancer	1.48e-05	3.88e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—IL2—thymus cancer	1.48e-05	3.88e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—IL2—thymus cancer	1.48e-05	3.87e-05	CbGpPWpGaD
Bosutinib—EGFR—Innate Immune System—AKT1—thymus cancer	1.43e-05	3.73e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—CD4—thymus cancer	1.42e-05	3.72e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—KIT—thymus cancer	1.41e-05	3.69e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—IL2—thymus cancer	1.4e-05	3.65e-05	CbGpPWpGaD
Bosutinib—SRC—Developmental Biology—AKT1—thymus cancer	1.38e-05	3.61e-05	CbGpPWpGaD
Bosutinib—ERBB3—Disease—AKT1—thymus cancer	1.38e-05	3.61e-05	CbGpPWpGaD
Bosutinib—LCK—Innate Immune System—AKT1—thymus cancer	1.38e-05	3.6e-05	CbGpPWpGaD
Bosutinib—EGFR—Adaptive Immune System—AKT1—thymus cancer	1.37e-05	3.59e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—KIT—thymus cancer	1.36e-05	3.55e-05	CbGpPWpGaD
Bosutinib—SRC—Hemostasis—AKT1—thymus cancer	1.35e-05	3.54e-05	CbGpPWpGaD
Bosutinib—PTK2—Immune System—AKT1—thymus cancer	1.33e-05	3.48e-05	CbGpPWpGaD
Bosutinib—LCK—Adaptive Immune System—AKT1—thymus cancer	1.32e-05	3.46e-05	CbGpPWpGaD
Bosutinib—SRC—Disease—CD4—thymus cancer	1.31e-05	3.43e-05	CbGpPWpGaD
Bosutinib—YES1—Immune System—AKT1—thymus cancer	1.31e-05	3.43e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—IL2—thymus cancer	1.31e-05	3.42e-05	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—TP53—thymus cancer	1.3e-05	3.39e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—TP53—thymus cancer	1.28e-05	3.34e-05	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—AKT1—thymus cancer	1.27e-05	3.32e-05	CbGpPWpGaD
Bosutinib—IRAK1—Immune System—AKT1—thymus cancer	1.24e-05	3.25e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—TP53—thymus cancer	1.23e-05	3.22e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—IL2—thymus cancer	1.22e-05	3.19e-05	CbGpPWpGaD
Bosutinib—SRC—Innate Immune System—AKT1—thymus cancer	1.22e-05	3.19e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—KIT—thymus cancer	1.2e-05	3.14e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—IL2—thymus cancer	1.19e-05	3.11e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—TP53—thymus cancer	1.19e-05	3.1e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—TP53—thymus cancer	1.19e-05	3.1e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—AKT1—thymus cancer	1.17e-05	3.06e-05	CbGpPWpGaD
Bosutinib—SRC—Adaptive Immune System—AKT1—thymus cancer	1.17e-05	3.06e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—IL2—thymus cancer	1.17e-05	3.05e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—IL2—thymus cancer	1.15e-05	3e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—TP53—thymus cancer	1.14e-05	2.99e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—IL2—thymus cancer	1.14e-05	2.99e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling by GPCR—AKT1—thymus cancer	1.12e-05	2.93e-05	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—AKT1—thymus cancer	1.1e-05	2.87e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—AKT1—thymus cancer	1.08e-05	2.82e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—AKT1—thymus cancer	1.05e-05	2.74e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—AKT1—thymus cancer	1.04e-05	2.72e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—AKT1—thymus cancer	1.02e-05	2.68e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—TP53—thymus cancer	1.02e-05	2.66e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—TP53—thymus cancer	1e-05	2.63e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—AKT1—thymus cancer	1e-05	2.62e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—AKT1—thymus cancer	1e-05	2.62e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—AKT1—thymus cancer	9.99e-06	2.61e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—IL2—thymus cancer	9.92e-06	2.59e-05	CbGpPWpGaD
Bosutinib—LYN—Immune System—AKT1—thymus cancer	9.78e-06	2.56e-05	CbGpPWpGaD
Bosutinib—ABL1—Immune System—AKT1—thymus cancer	9.73e-06	2.55e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—AKT1—thymus cancer	9.66e-06	2.53e-05	CbGpPWpGaD
Bosutinib—FYN—Immune System—AKT1—thymus cancer	9.63e-06	2.52e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—AKT1—thymus cancer	9.58e-06	2.5e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—IL2—thymus cancer	9.56e-06	2.5e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—TP53—thymus cancer	9.52e-06	2.49e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—AKT1—thymus cancer	9.45e-06	2.47e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—AKT1—thymus cancer	9.22e-06	2.41e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—AKT1—thymus cancer	9.1e-06	2.38e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—TP53—thymus cancer	8.97e-06	2.35e-05	CbGpPWpGaD
Bosutinib—FYN—Disease—AKT1—thymus cancer	8.89e-06	2.32e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—AKT1—thymus cancer	8.84e-06	2.31e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—AKT1—thymus cancer	8.6e-06	2.25e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—AKT1—thymus cancer	8.48e-06	2.22e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—IL2—thymus cancer	8.46e-06	2.21e-05	CbGpPWpGaD
Bosutinib—EGFR—Immune System—AKT1—thymus cancer	8.32e-06	2.18e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—AKT1—thymus cancer	8.04e-06	2.1e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—AKT1—thymus cancer	8.01e-06	2.1e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—TP53—thymus cancer	7.84e-06	2.05e-05	CbGpPWpGaD
Bosutinib—EGFR—Disease—AKT1—thymus cancer	7.68e-06	2.01e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—TP53—thymus cancer	7.65e-06	2e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—AKT1—thymus cancer	7.57e-06	1.98e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—TP53—thymus cancer	7.49e-06	1.96e-05	CbGpPWpGaD
Bosutinib—LCK—Disease—AKT1—thymus cancer	7.4e-06	1.94e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—TP53—thymus cancer	7.37e-06	1.93e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—TP53—thymus cancer	7.33e-06	1.92e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—AKT1—thymus cancer	7.1e-06	1.86e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—AKT1—thymus cancer	6.62e-06	1.73e-05	CbGpPWpGaD
Bosutinib—SRC—Disease—AKT1—thymus cancer	6.55e-06	1.71e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—AKT1—thymus cancer	6.46e-06	1.69e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—TP53—thymus cancer	6.37e-06	1.67e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—AKT1—thymus cancer	6.32e-06	1.65e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—AKT1—thymus cancer	6.22e-06	1.63e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—AKT1—thymus cancer	6.19e-06	1.62e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—TP53—thymus cancer	6.14e-06	1.6e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—TP53—thymus cancer	5.43e-06	1.42e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—AKT1—thymus cancer	5.38e-06	1.41e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—AKT1—thymus cancer	5.18e-06	1.36e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—AKT1—thymus cancer	4.59e-06	1.2e-05	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—AKT1—thymus cancer	3.25e-06	8.49e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—AKT1—thymus cancer	2e-06	5.23e-06	CbGpPWpGaD
